Cytos VLP Platform is Basis for Phase 1 Clinical Trial with Anti-IgE Vaccine

 Cytos VLP Platform is Basis for Phase 1 Clinical Trial with Anti-IgE Vaccine

PR Newswire

ZURICH, February 4, 2013

ZURICH, February 4, 2013 /PRNewswire/ --

Cytos Biotechnology Ltd (SIX:CYTN) has been informed by Pfizer Inc. that the
first patient has been dosed in a Phase 1 clinical trial with an anti-IgE
vaccine, which is being developed under a license agreement between both
parties. Pfizer's anti-IgE vaccine is based on Cytos' VLP
("virus-like-particle") vaccine platform.

Christian Itin, Chairman and Chief Executive Officer of Cytos, comments: "We
are very pleased that Pfizer has advanced its anti-IgE vaccine to a Phase 1
clinical trial. This is an important milestone for the program and provides
further evidence of the potential of Cytos' B-cell vaccine platform based on
Qbeta-derived virus like particles."

Pfizer acquired world-wide exclusive rights to develop, manufacture and
commercialize certain specified vaccines based on Cytos' VLP platform in 2009.

About Cytos Biotechnology Ltd

Cytos is a public biopharmaceutical company focused on the development of
targeted immuno-therapies. The Company's lead product candidate CYT003 is a
first-in-class biologic in Phase 2 clinical development as a potential new
treatment for allergic asthma.

CYT003 acts via a novel, allergen-independent mechanism of action to
selectively suppress the body's immune response to allergens, a predominant
risk factor for asthma. In a successfully completed Phase 2a study, CYT003 was
shown to maintain asthma control and lung function and asthma control in
patients with persistent allergic asthma, even as standard inhaled
corticosteroid treatment was withdrawn. CYT003 has been shown to be safe in
over 450 patients to date.

Cytos was founded in 1995 as a spinoff from the Swiss Federal Institute of
Technology (ETH) in Zurich. It is located in Schlieren (Zurich), Switzerland.
The Company is listed according to the Main Standard on the SIX Swiss Exchange
Ltd under the symbol CYTN.

This foregoing press release may contain forward-looking statements that
include words or phrases such as "are intended for", "are designed to", or
other similar expressions. These forward-looking statements are subject to a
variety of significant uncertainties, including scientific, business, economic
and financial factors, and therefore actual results may differ significantly
from those presented. There can be no assurance that any further therapeutic
entities will enter clinical trials, that clinical trial results will be
predictive for future results, that therapeutic entities will be the subject
of filings for regulatory approval, that any drug candidates will receive
marketing approval from the U.S. Food and Drug Administration or equivalent
regulatory authorities, or that drugs will be marketed successfully. Against
the background of these uncertainties readers should not rely on
forward-looking statements. The Company assumes no responsibility to update
forward-looking statements or adapt them to future events or developments.


Contact: For further information, please contact: Cytos Biotechnology Ltd:
Harry Welten, Chief Financial Officer, Tel: +41-44-733-46-46, e-mail: US Investor enquiries: Susan A. Noonan, Tel:
+1-(212)-966-3650, e-mail:
Press spacebar to pause and continue. Press esc to stop.